Tianyu Pharmaceutical (300702.SZ): Apalutamide Active Pharmaceutical Ingredient Passes CDE Review

Stock News01-07

Zhejiang Tianyu Pharmaceutical Co., Ltd. (300702.SZ) announced that the Apalutamide active pharmaceutical ingredient (API), developed by its wholly-owned subsidiary Zhejiang Kingsun Pharmaceutical Co., Ltd. ("Kingsun Pharmaceutical"), has recently passed the review conducted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration. Apalutamide is a non-steroidal anti-androgen drug used for the treatment of prostate cancer; it functions by inhibiting the androgen receptor signaling pathway, thereby delaying disease progression. It is primarily indicated for non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC) and must be used in combination with castration therapy under a physician's guidance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1108451879?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-07 16:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108451879","market":"sh","top_or_hot":-1,"title":"Tianyu Pharmaceutical (300702.SZ): Apalutamide Active Pharmaceutical Ingredient Passes CDE Review","media":"Stock News","content":"<p>Zhejiang Tianyu Pharmaceutical Co., Ltd. (300702.SZ) announced that the Apalutamide active pharmaceutical ingredient (API), developed by its wholly-owned subsidiary Zhejiang Kingsun Pharmaceutical Co., Ltd. (\"Kingsun Pharmaceutical\"), has recently passed the review conducted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration.\nApalutamide is a non-steroidal anti-androgen drug used for the treatment of prostate cancer; it functions by inhibiting the androgen receptor signaling pathway, thereby delaying disease progression. It is primarily indicated for non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC) and must be used in combination with castration therapy under a physician's guidance.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tianyu Pharmaceutical (300702.SZ): Apalutamide Active Pharmaceutical Ingredient Passes CDE Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTianyu Pharmaceutical (300702.SZ): Apalutamide Active Pharmaceutical Ingredient Passes CDE Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-07 16:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zhejiang Tianyu Pharmaceutical Co., Ltd. (300702.SZ) announced that the Apalutamide active pharmaceutical ingredient (API), developed by its wholly-owned subsidiary Zhejiang Kingsun Pharmaceutical Co., Ltd. (\"Kingsun Pharmaceutical\"), has recently passed the review conducted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration.\nApalutamide is a non-steroidal anti-androgen drug used for the treatment of prostate cancer; it functions by inhibiting the androgen receptor signaling pathway, thereby delaying disease progression. It is primarily indicated for non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC) and must be used in combination with castration therapy under a physician's guidance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"300702","symbol_name":"天宇股份","start_time":0,"source_url":"","article_id":"1108451879","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108451879","pubTimestamp":1767773445,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Zhejiang Tianyu Pharmaceutical Co., Ltd. (300702.SZ) announced that the Apalutamide active pharmaceutical ingredient (API), developed by its wholly-owned subsidiary Zhejiang Kingsun Pharmaceutical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300702":"天宇股份","LU1223082196.USD":"施罗德环球黄金A Acc","LU1223083913.SGD":"Schroder ISF Global Gold A Acc SGD-H","BK4017":"黄金","LU1223082519.USD":"SCHRODER ISF GLOBAL GOLD \"A\" (USD) INC AV","CDE":"科尔黛伦矿业","BK0239":"医药制造"},"translate_title":"天宇药业（300702.SZ）：阿帕鲁胺活性药物成分通过CDE审评","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300702":1,"CDE":1},"content_text":"Zhejiang Tianyu Pharmaceutical Co., Ltd. (300702.SZ) announced that the Apalutamide active pharmaceutical ingredient (API), developed by its wholly-owned subsidiary Zhejiang Kingsun Pharmaceutical Co., Ltd. (\"Kingsun Pharmaceutical\"), has recently passed the review conducted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration.\nApalutamide is a non-steroidal anti-androgen drug used for the treatment of prostate cancer; it functions by inhibiting the androgen receptor signaling pathway, thereby delaying disease progression. It is primarily indicated for non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC) and must be used in combination with castration therapy under a physician's guidance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1108451879","isCrawlerRequest":true}